What are your top takeaways from AHA 2026?

The Lp(a) HORIZON trial is certainly thought-provoking. While pelacarsen produced substantial Lp(a) lowering, the HORIZON trial did not demonstrate a reduction in major cardiovascular outcomes. At the same time, the study reinforces something we already know works: aggressive control of established ...

This was an impactful AHA Scientific Sessions meeting with notable science in prevention, including major trials of agents to lower Lp(a) and inflammation. The meeting was further highlighted by Dr. Eric Topol, who challenged us all to think differently and to seize missed opportunities in cardiovas...